Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 3/20 | 0.43 |
| ▸ | PGK2 | P07205 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556536 | 0.77 | PGK1 (0.47) | PGK1PGK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10223189 | 0.76 | HRH1 (0.44) | HRH1KLKB1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4848422 | 0.74 | PGK1 (0.44) | PGK1PGK2FDPS | |
| SCHEMBL11926965 | 0.74 | HRH1 (0.45) | HRH1KLKB1 | |
| SCHEMBL25426497 | 0.73 | PGK1 (0.47) | PGK1PGK2SMN1; SMN2 | |
| SCHEMBL7079640 | 0.73 | HRH1 (0.42) | HRH1KLKB1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4849187 | 0.72 | SLC6A3 (0.44) | PGK1PGK2HRH1FDPSALDH1A1 | |
| SCHEMBL20536448 | 0.72 | PGK1 (0.43) | PGK1PGK2FDPSSMN1; SMN2 | |
| SCHEMBL12926881 | 0.72 | HRH1 (0.44) | HRH1KLKB1 | |
| SCHEMBL3760695 | 0.72 | HRH1 (0.44) | HRH1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | PGK1 3240/4885PGK2 3966/4885HRH1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.